5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 15.13▲ | 15.15▲ | 15.11▲ | 15.26▼ | 16.25▼ |
MA10 | 15.09▲ | 15.12▲ | 15.15▲ | 15.60▼ | 16.39▼ |
MA20 | 15.11▲ | 15.16▲ | 15.41▼ | 16.36▼ | 15.67▼ |
MA50 | 15.10▲ | 15.37▼ | 15.37▼ | 16.50▼ | 21.58▼ |
MA100 | 15.14▲ | 15.40▼ | 15.79▼ | 15.81▼ | 27.20▼ |
MA200 | 15.35▼ | 15.88▼ | 16.79▼ | 19.99▼ | 19.41▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.012▲ | 0.013▲ | -0.020▼ | -0.149▼ | 0.367▲ |
RSI | 63.774▲ | 49.820▼ | 47.586▼ | 41.112▼ | 38.159▼ |
STOCH | 83.546▲ | 59.490 | 30.867 | 36.477 | 48.201 |
WILL %R | 0.000▲ | -17.241▲ | -63.636 | -67.857 | -69.314 |
CCI | 140.963▲ | 49.390 | -31.238 | -98.030 | -60.011 |
Friday, August 15, 2025 06:30 AM
Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers including Brepocitinib's Phase 3 potential.
|
Tuesday, August 12, 2025 12:35 AM
Roivant Sciences Ltd (ROIV) reports a robust $4.5 billion cash reserve, completes a significant share repurchase program, and navigates ongoing legal and market uncertainties.
|
Monday, August 11, 2025 09:29 AM
Discover key insights from Roivant Sciences' Q1 2025 earnings call, including brepocitinib DM data milestones, financial strength, and strategic ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 15.31 | 15.31 | 14.98 | 15.22 | 1,781,381 |
14/08/25 | 15.61 | 15.755 | 15.135 | 15.20 | 1,051,811 |
13/08/25 | 15.35 | 16.18 | 15.14 | 15.89 | 1,055,403 |
12/08/25 | 14.85 | 15.42 | 14.85 | 15.21 | 1,370,129 |
11/08/25 | 15.50 | 15.60 | 14.32 | 14.76 | 1,687,903 |
08/08/25 | 15.66 | 16.085 | 15.16 | 15.46 | 646,898 |
07/08/25 | 16.15 | 16.43 | 15.54 | 15.73 | 688,904 |
06/08/25 | 16.28 | 16.4841 | 15.58 | 15.96 | 840,771 |
05/08/25 | 16.11 | 16.555 | 15.64 | 16.51 | 1,212,392 |
04/08/25 | 15.78 | 16.11 | 15.49 | 16.09 | 716,034 |
|
|
||||
|
|
||||
|
|